Biotech bil­lion­aire Róbert Wess­man en­gi­neers $450M deal for Alvo­gen sub­sidiaries

Alvo­gen is hand­ing off two of its sub­sidiaries to CEO Róbert Wess­man and his health­care in­vest­ment firm Az­tiq — who has now tied the two to­geth­er in a mas­sive biobucks deal.

In an al­liance with Thai­land’s PTT Group sub­sidiary In­no­bic, the two com­pa­nies signed an agree­ment last week to buy a 100% stake in Alvo­gen Emerg­ing Mar­ket Hold­ings Lim­it­ed (AEMH) for $475 mil­lion from Alvo­gen, buy­ing out share­hold­ers such as CVC Cap­i­tal Part­ners and Sin­ga­pore’s Temasek. And now, the group is the ma­jor­i­ty share­hold­er of Alvo­gen’s for­mer Asian sub­sidiary Lo­tus Phar­ma­ceu­ti­cals and the on­ly share­hold­er of Alvo­gen Mal­ta, the own­er of B2B phar­ma Adal­vo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER